Supercharged immune cells take on childhood leukemia
NCT ID NCT01860937
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests the safety of giving patients their own genetically modified T-cells to fight relapsed B-cell acute lymphoblastic leukemia. The study includes children and young adults up to age 26 whose leukemia has returned or is hard to treat. The modified T-cells are designed to target and destroy cancer cells, with the goal of finding a safe dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital
Boston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.